Document is current
Any future updates will be listed below
-
Authors
De Jonghe, Joachim https://orcid.org/0000-0003-0584-8265
Opzoomer, James W.
Vilas-Zornoza, Amaia
Crane, Peter
Nilges, Benedikt S.
Vicari, Marco https://orcid.org/0000-0002-3042-6278
Lee, Hower https://orcid.org/0000-0002-8781-3623
Lara-Astiaso, David
Gross, Torsten
Morf, Jörg https://orcid.org/0000-0002-0485-3380
Schneider, Kim
Cudini, Juliana
Ramos-Mucci, Lorenzo
Mooijman, Dylan
Tiklová, Katarína
Salas, Sergio Marco
Langseth, Christoffer Mattsson
Kashikar, Nachiket D. https://orcid.org/0000-0002-4466-7486
Roberts, Charles E. S.
,
Langseth, Christoffer Mattsson
Carrami, Eli M.
McIntyre, Rebecca
Swerner, Casey Benjamin
Hessel, Edith M.
Kapourani, Chantriolnt-Andreas
Regep, Cristian
Schapiro, Denis
Lundeberg, Joakim https://orcid.org/0000-0003-4313-1601
Nilsson, Mats https://orcid.org/0000-0001-9985-0387
Shalek, Alex K. https://orcid.org/0000-0001-5670-8778
Cribbs, Adam P. https://orcid.org/0000-0001-5288-3077
Taylor-King, Jake P. https://orcid.org/0000-0002-1025-0041
- License Information
-
More Information
Article History
First Online: 17 July 2024
Competing interests
: J.D.J. is an inventor on patent applications submitted by the University of Cambridge (via its technology transfer office, Cambridge Enterprise). J.W.O. is an inventor on a patent application related to single-cell sequencing filed by UCLB. A.P.C is an inventor on several patent applications related to single-cell sequencing filed by Oxford University Innovations. J.W.O., A.V.Z., T.G., J.C., L.R.M., C.E.S.R., A.K.S. and J.P.T.-K. receive compensation from Relation Therapeutics. P.C. and A.P.C. are employees of Caeruleus Genomics. B.S.N. and N.D.K. receive compensation from OMAPiX. M.V. and J.L. are currently scientific consultants for 10x Genomics. J.M. receives compensation from Skyhawk Therapeutics and previously worked as a scientific consultant for Scipio Bioscience. K.S. receives compensation from Roche. D.M. receives compensation from scDiscoveries. H.L., S.M.S. and C.M.L. receive compensation from spatialist. C.E.S.R. also receives compensation from ARK Investment Management and Freenome. A.K.S. reports compensation for consulting and/or scientific advisory board membership from Honeycomb Biotechnologies, Cellarity, Ochre Bio, Relation Therapeutics, FL86, IntrECate Biotherapeutics, Senda Biosciences and Dahlia Biosciences.
